ABSTRACT
Background: The gut microbiome plays an important role in the lipid metabolism. Antibiotic treatment causes changes in the intestinal microbiota. Our objective was to explore the relationship between changes in the intestinal microbiota and the level of plasma high density lipoprotein cholesterol (HDL) and low density lipoprotein cholesterol (LDL). Methods: Prospective case-control study with Helicobacter pylori-positive patients undergoing eradication therapy with omeprazole, clarithromycin, and amoxicillin. Stool and blood samples were obtained from 20 controls (H. pylori negative) and 40 patients before and 2 months after antibiotic treatment. Gut microbiota was determined through 16S rRNA amplicon sequencing (Illumina MiSeq). Results: Eradication treatment for H. pylori increased the HDL levels, and caused changes in gut microbiota profiles. An unfavorable lipid profiles (high LDL and low HDL levels) was associated with a low microbial richness and an increase of the Bacteroidetes phylum. Prevotella copri, Lachonobacterium, and Delsufovibrio were positively associated with HDL while Rikenellaceae was negatively associated with HDL after completing antibiotic treatment. Conclusions: Helicobacter pylori eradication treatment could improve lipid metabolism in relation with an increase in the HDL. Changes in the abundance of specific bacteria, such as P. copri, Lachonobacterium, Delsufovibrio, and Rikenellaceae could be associated with change in the plasma HDL levels.
ABSTRACT
Objetivo. Evaluar el tratamiento de la diabetes pregestacional (DPG) y los resultados metabolicoperinatales en función del mismo. Marterial y métodos. Se analiza a 42 mujeres con DPG en tratamiento insulínico intensivo seguidas desde el primer trimestre de gestación. Resultados. La edad media fue de 30±5 años y el tiempo medio±desviación estándar de diabetes fue de 14,2±9,5 años. El índice de masa corporal (IMC) y los requerimientos de insulina pasaron de 26±4,85kg/m2 y 0,56±0,32 U/kg al inicio a 30±4,5kg/m2 y 0,70±0,28 U/kg al final. La hemoglobina glucosilada (HbA1c) previa era de 7,71±1,85% y la media gestacional de 6,81±1,33%. Se aplicaron 4 modalidades de insulina: NPH-lispro 26,2%, mezclas prefijadas 26,2%, glargina-lispro 21,4% e ISCI 26,2%. No hubo diferencias significativas entre el tipo de insulina y las variables analizadas. Conclusiones. El tipo de insulina no afecta a los resultados perinatales. Las HbA1c elevadas se relacionan con mayor circunferencia abdominal a las 32 semanas y más incidencia de partos pretérmino (AU)
Aim. To evaluate the treatment of pregestational diabetes mellitus (PDM) and the metabolicperinatal results according to the treatment used. Material and method. We reviewed 42 women with PDM with intensive insulin treatment under clinical supervision from the first three months of their pregnancy. Results. The average age was 30±5 years and the time for the average development of diabetes was14,2±9.5 years. The Body Mass Index and the need for insulin passed from 26±4.85kg/m2 and 0,56±0.32 U/kg at the beginning to 30±4.5kg/m2 and 0.70±0.28 U/kg at the end. Prior HbA1c was 7.71±1.85% and a gestational average HbA1c of 6.81±1.33%. Four types of insulin therapy were used: NPH-lispro 26.2%, pre-programmed mixtures 26.2%, glargina-lispro 21.4% and ISCI 26,2%. Significant differences were not found among the types of insulin and the variables analyzed. Conclusions. The type of insulin doesnt affect perinatal results. High HbA1c are related to greater abdominal circumference at 32 weeks and with a greater (AU)
